CHM CORE NK Combination Phase 1b trial update

Sydney, Australia, 13 November 2025: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, advises that the CHM CORE-NK + Vactosertib Phase 1b clinical trial has been temporarily suspended due to the unavailability of trial material unrelated to the combination of CHM CORE NK and Vactosertib. It is expected that the supply chain issue will be resolved